ArticlePathology oncology research : POR2013
Overexpression of CD73 in prostate cancer is associated with lymph node metastasis.
Article in Pathology oncology research : POR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 65 citations in OpenAlex.
- CD73 inhibition overcomes adaptive immune resistance to PARP inhibition in models of prostate cancer.The Journal of clinical investigation · 2026Article
- Evaluating the Serum Levels of CD73 in Patients with Head and Neck Squamous Cell Carcinoma.Journal of dentistry (Shiraz, Iran) · 2026Article
- Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.Discover oncology · 2026Article
- CD73 is associated with glycolysis related metabolic programs and CD8Frontiers in immunology · 2026Article
- Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Article
- MicroRNA: Crucial modulator in purinergic signalling involved diseases.Purinergic signalling · 2023Review
- Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study.International journal of clinical oncology · 2022Article
- Review
- CD73 promotes cervical cancer growth via EGFR/AKT1 pathway.Translational cancer research · 2022Article
- Pan-cancer analysis identifies NT5E as a novel prognostic biomarker on cancer-associated fibroblasts associated with unique tumor microenvironment.Frontiers in pharmacology · 2022Article
- Targeting the spectrum of immune checkpoints in prostate cancer.Expert review of clinical pharmacology · 2021Review
- Article
- Varied functions of immune checkpoints during cancer metastasis.Cancer immunology, immunotherapy : CII · 2021Review
- Characterization of a dual media system for culturing primary normal and Fuchs endothelial corneal dystrophy (FECD) endothelial cells.PloS one · 2021Article
- Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?British journal of clinical pharmacology · 2020Review
- CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts.BMC cancer · 2019Article
- Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy.Immune network · 2019Review
- NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer.Bioscience reports · 2019Article
- CD73 a novel marker for the diagnosis of benign and malignant salivary gland tumors.Journal of clinical and experimental dentistry · 2019Article
- CD73 expression in normal and pathological human hepatobiliopancreatic tissues.Cancer immunology, immunotherapy : CII · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common malignancy in men in Europe and North America. At present, it is becoming an increasingly common cancer in China. CD73 (ecto-5'-nucleotidase) is a glycosylphosphatidylinositol (GPI)-linked 70-kDa cell surface enzyme. It is also broadly expressed in many types of tissues. Recent studies have showed that CD73 is widely expressed on malignancies and is up-regulated in cancerous tissues. Consequently, we analyzed the expression of CD73 in prostate cancer tissue. The expression of the CD73 protein was evaluated by Immunohistochemistry staining in 116 tissue specimens. The expression was further examined by quantitative real-time PCR (qRT-PCR) and Western blot in the same set of patients. The intense cell membrane staining for the CD73 protein was observed. The expression of CD73 in lymph node non-metastasizing prostate cancer tissues can be seen at low levels, and is generally undetectable. RT-PCR and Western blot showed that the expression of CD73 in lymph node metastasizing prostate cancer was higher compared with non-metastasizing ones. These results suggest that CD73 could be considered as a relevant-specific target for molecular therapy of prostate cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.